Literature DB >> 19654203

Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).

M Troch, C Zielinski, M Raderer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654203     DOI: 10.1093/annonc/mdp349

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

Review 1.  Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature.

Authors:  Barbara Kiesewetter; Andrés J M Ferreri; Markus Raderer
Journal:  Oncologist       Date:  2015-07-08

2.  Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.

Authors:  Barbara Kiesewetter; Marlene Troch; Marius E Mayerhoefer; Werner Dolak; Ingrid Simonitsch-Klupp; Markus Raderer
Journal:  Oncologist       Date:  2015-11-30

3.  A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma).

Authors:  Barbara Kiesewetter; Marlene Troch; Werner Dolak; Leonhard Müllauer; Julius Lukas; Christoph C Zielinski; Markus Raderer
Journal:  Haematologica       Date:  2012-08-16       Impact factor: 9.941

4.  Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.

Authors:  Barbara Kiesewetter; Wolfgang Lamm; Ortrun Neuper; Marius E Mayerhoefer; Ingrid Simonitsch-Klupp; Markus Raderer
Journal:  Hematol Oncol       Date:  2019-07-28       Impact factor: 5.271

Review 5.  Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma.

Authors:  Sung-Hsin Kuo; Kun-Huei Yeh; Chung-Wu Lin; Jyh-Ming Liou; Ming-Shiang Wu; Li-Tzong Chen; Ann-Lii Cheng
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.